Levosimendan

Drug Profile

Levosimendan

Alternative Names: Daxim; ODM 109; OR-1259; Oral levosimendan - Orion; Simdax

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics
  • Class Antiarrhythmics; Cardiotonics; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Low cardiac output
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Low cardiac output
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Chronic heart failure; Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 08 Feb 2017 Orion completes a phase II trial in Amyotrophic lateral sclerosis in United Kingdom, Germany, Ireland and Netherlands (NCT02487407)
  • 31 Jan 2017 Tenax therapeutics announced its plans to meet with the US FDA to discuss preliminary results of the phase III LEVO-CTS study and future development steps
  • 29 Nov 2016 Tenax Therapeutics initiates expanded access for Acute heart failure (In neonates, In infants, In children, In adolescent) in USA (NCT02973620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top